Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) EBITDA (2016 - 2025)

Immucell's EBITDA history spans 16 years, with the latest figure at -$1.9 million for Q4 2025.

  • For Q4 2025, EBITDA fell 206.21% year-over-year to -$1.9 million; the TTM value through Dec 2025 reached -$215976.0, up 52.09%, while the annual FY2025 figure was -$215976.0, 52.09% up from the prior year.
  • EBITDA reached -$1.9 million in Q4 2025 per ICCC's latest filing, down from $20075.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $4.5 million in Q4 2023 to a low of -$2.3 million in Q1 2023.
  • Average EBITDA over 5 years is -$145825.4, with a median of -$337338.5 recorded in 2021.
  • Peak YoY movement for EBITDA: tumbled 1223.53% in 2022, then soared 472.48% in 2025.
  • A 5-year view of EBITDA shows it stood at $145412.0 in 2021, then crashed by 1223.53% to -$1.6 million in 2022, then surged by 377.67% to $4.5 million in 2023, then plummeted by 60.08% to $1.8 million in 2024, then plummeted by 206.21% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's EBITDA are -$1.9 million (Q4 2025), $20075.0 (Q3 2025), and $569562.0 (Q2 2025).